Caterina Cecchetti

Site-specific biology of tongue base aggressive B-cell lymphomas revealed by molecular subtype classification

Davide Chizzoniti, Caterina Cecchetti, Federica Melle, Lorena Appio et autres

Not available.

it (code pays fourni par la source)

Late-onset progressive multifocal leukoencephalopathy after teclistamab in multiple myeloma: extending the timeline of infectious risk

Davide Chizzoniti, Fabrizio Ciambelli, Maria Luisa Latargia, Luca Canziani et autres

Not available.

it, cr (code pays fourni par la source)

Interim-PET predicts progression-free survival in stage IV Hodgkin lymphoma treated with upfront brentuximab vedotin-AVD

Chiara Rusconi, Angelica Barone, Andrea Visentin, Benedetta Bianchi et autres

Brentuximab vedotin (BV) plus doxorubicin, vinblastine and dacarbazine (AVD) demonstrated to improve survival compared to ABVD as frontline treatment of advanced stage Hodgkin Lymphoma (HL). We retrospectively collected data of 99 stage IV HL patients treated off-protocol with BV-AVD to evaluate the …

it, us (code pays fourni par la source)

Primary cutaneous, epidermotropic mycosis fungoides-like presentation: critical appraisal and description of two novel cases, broadening the spectrum of ALK+ T-cell lymphoma

Giorgio Alberto Croci, Lorena Appio, Caterina Cecchetti, Silvia Tabano et autres

it (code pays fourni par la source)

Gamma/delta T‐cell lymphoma with mycosis fungoides‐like clinical course transforming to “T‐cell‐receptor‐silent” aggressive lymphoma: Description of one case

Dario Tomasini, Giorgio Alberto Croci, Annamaria Hotz, Stefania Cione et autres

Primary cutaneous γδ T-cell lymphomas (PCGDTLs) are a heterogeneous group of lymphomas representing about 1% of primary cutaneous T-cell lymphomas (CTCLs) and mostly regarded as clinically aggressive. Current WHO-EORTC classification recognizes different clinic-pathologic subsets of PCGDTL, but it suggests that cases showing …

it (code pays fourni par la source)

Long‐lasting efficacy and safety of lenalidomide maintenance in patients with relapsed diffuse large B‐cell lymphoma who are not eligible for or failed autologous transplantation

Andrés J.M. Ferreri, Marianna Sassone, Piera Angelillo, Francesco Zaja et autres

We report final results of a phase II trial addressing efficacy and feasibility of lenalidomide maintenance in patients with chemosensitive relapse of diffuse large B-cell lymphoma (DLBCL) not eligible for or failed after autologous stem cell transplantation (ASCT). Patients with relapsed DLBCL …

it, ua (code pays fourni par la source)

Author response for "LONG-LASTING EFFICACY AND SAFETY OF LENALIDOMIDE MAINTENANCE IN PATIENTS WITH RELAPSED DIFFUSE LARGE B-CELL LYMPHOMA WHO ARE NOT ELIGIBLE FOR OR FAILED AUTOLOGOUS TRANSPLANTATION"

Andrés J.M. Ferreri, Marianna Sassone, Piera Angelillo, Francesco Zaja et autres

Treatment of MALT lymphoma of the conjunctiva with intralesional rituximab supplemented with autologous serum

Andrés J.M. Ferreri, Marianna Sassone, Elisabetta Miserocchi, Silvia Govi et autres

Patients with indolent conjunctival lymphomas exhibit good prognosis, with exceptional cases of dissemination, and are suitable candidates for intralesional therapies. We report the first prospective phase 2 trial using intralesional rituximab supplemented with autologous serum in adults with relapsed/refractory indolent CD20+ lymphoma …

us, it (code pays fourni par la source)

LONG‐TERM EFFICACY AND SAFETY OF LENALIDOMIDE MAINTENANCE IN PATIENTS WITH RELAPSED DIFFUSE LARGE B‐CELL LYMPHOMA WHO ARE NOT ELIGIBLE FOR AUTOLOGOUS TRANSPLANTATION (ASCT)

Andrés J.M. Ferreri, Marianna C. Sassone, Piera Angelillo, Francesco Zaja et autres

Background: A multicentre phase II trial showed that lenalidomide (LENA) maintenance was well tolerated and improved outcome in pts with chemosensitive relapse of DLBCL not eligible for or relapsed after ASCT (NCT00799513). However, late side effects and events remained undefined as median …

it (code pays fourni par la source)

R‐CHOP PRECEDED BY ENGINEERED TUMOR NECROSIS FACTOR (TNF) IN RELAPSED OR REFRACTORY PRIMARY DIFFUSE LARGE B‐CELL LYMPHOMA OF THE CNS (rPCNSL): FINAL RESULTS OF THE INGRID TRIAL

Andrés J.M. Ferreri, Teresa Calimeri, G. Del Conte, Maurilio Ponzoni et autres

Background: Patients (pts) with PCNSL are usually treated with high-dose methotrexate-based combinations that are not currently used in other DLBCL and require hospitalization and extensive expertise to manage toxicity. The use of R-CHOP could overcome these difficulties, but CNS availability of related …

it (code pays fourni par la source)

R-CHOP preceded by blood-brain barrier permeabilization with engineered tumor necrosis factor-α in primary CNS lymphoma

Andrés J.M. Ferreri, Teresa Calimeri, Gian Marco Conte, Dario Cattaneo et autres

Abstract Patients with primary central nervous system lymphoma (PCNSL) are treated with high-dose methotrexate-based chemotherapy, which requires hospitalization and extensive expertise to manage related toxicity. The use of R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) could overcome these difficulties, but blood-brain barrier …

it, us (code pays fourni par la source)

Multicenter Phase II Trial Addressing Lenalidomide Maintenance in Patients with Relapsed Diffuse Large B-Cell Lymphoma (rDLBCL) Who Are Not Eligible for Autologous Stem Cell Transplantation (ASCT): Efficacy and Safety Results after a Median Follow-up of Five Years

Andrés JM Ferreri, Marianna Sassone, Francesco Zaja, Alessandro Re et autres

Abstract Background: Lenalidomide (LENA) maintenance is associated with significantly improved outcome in patients (pts) with chemosensitive relapse of DLBCL not eligible for ASCT or experiencing relapse after ASCT. Preliminary results of a multicentre phase II trial (NCT00799513), reported after a median follow-up …

it, ua (code pays fourni par la source)